Moderna, Merck mRNA Vaccine Shows Promise Against Melanoma Recurrence

Moderna and Merck have announced promising results from a joint trial of their mRNA vaccine aimed at preventing the return of melanoma, one of the deadliest forms of skin cancer. The Food and Drug Administration-approved trial showed that this personalized therapy was effective in blocking the recurrence of melanoma.

The researchers behind the study are optimistic that these findings could have implications for other types of cancers as well.

These mRNA vaccines work by instructing cells to produce a specific protein that triggers an immune response, which can help prevent cancer from returning. In this trial, the vaccine was tailored to each individual's unique genetic profile.